Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026

Silexion Therapeutics Corp

2026-Q1 EPS reported $0.85 vs consensus -$1.32 ▲ beat (+164.6%)

Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.
Cash and equivalents $2.4M at Mar 31, 2026, down from $6.0M at Dec 31, 2025; post-quarter capital raises of $1.0M from warrant inducement.
Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer; CTA submitted to Germany.
Phase 2/3 trial initiation remains on track for Q2 2026 with safety run-in of ~18 patients, then randomized cohort of ~166.
Company believes post-quarter equity transactions restored Nasdaq compliance with $2.5M minimum shareholders' equity requirement.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.